Recursion Pharmaceuticals has received a consensus Hold rating from six analysts tracked by MarketBeat, with one sell, three hold and two buy ratings. The average 12-month price target stands at $9.40. On December 17, JPMorgan Chase & Co. upgraded to Overweight and raised its target from $10.00 to $11.00. Morgan Stanley also set an $11.00 target on the same date. UBS Group repeated its $11.00 target, while Weiss Ratings maintained its Sell (D-) rating on October 8.

Director Blake Borgeson sold 220,000 shares on January 6 at an average of $4.36, realizing $959,200 and reducing his stake by 3.20% to 6,649,863 shares valued at $28.99 million. CFO Ben R. Taylor disposed of 21,383 shares on December 29 at $4.18 each for proceeds of $89,380.94, a 2.73% ownership reduction to 761,550 shares worth $3.18 million. Over the past 90 days, insiders have sold 585,786 shares for $2.56 million, leaving insiders with 8.43% ownership.

UBS Asset Management Americas boosted its stake by 183.7% in Q1, acquiring 4.15 million additional shares to reach 6.41 million shares valued at $33.90 million. Norges Bank initiated a position in Q2 worth $16.04 million, while Bank Pictet & Cie Europe AG opened a $7.95 million stake in Q3. Stratos Wealth Partners increased its Q2 holding by 724.3%, adding 86,730 shares for a total of 98,704 shares valued at $499,000. Ethic Inc. also debuted with a $107,000 position. Hedge funds and institutions now own 89.06% of the company.

In Q3, Recursion reported revenue of $5.18 million, down 80.1% year-over-year and missing analyst forecasts of $19.36 million. EPS loss of $0.36 beat expectations by $0.02. The company carries a debt-to-equity ratio of 0.01, with both current and quick ratios at 4.60, indicating strong liquidity. Its 52-week trading range spans from $3.79 to $12.36, and beta stands at 0.95. On average, analysts forecast a full-year EPS loss of $1.57.